A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by activating the mother’s immune system to generate defence proteins, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the point of delivery, precisely when they are most vulnerable to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85% coverage when immunised 4 weeks before birth
- Maternal antibodies transferred through the placenta protect newborns from birth
- Coverage possible with two-week gap before premature birth
- Vaccination during third trimester still offers meaningful protection for infants
Compelling evidence from recent research
The performance of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation undertaken in England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing strong and reliable information of the vaccine’s real-world impact. The study’s results have been endorsed by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and prospective parents with assurance in the vaccine’s demonstrated effectiveness across varied populations and settings.
The results paint a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This clear distinction underscores the vaccine’s critical role in preventing serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Research approach and coverage
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospitalisations. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology captured actual clinical results rather than controlled laboratory conditions, providing practical evidence of how the vaccine functions when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its threats
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it extremely challenging for infected babies to breathe and feed effectively. Parents often witness their babies struggling visibly, their chests rising whilst they attempt to draw adequate oxygen into their damaged lungs. Whilst most infants recover with clinical support, a modest yet notable proportion perish from RSV complications yearly, making immunisation programmes a critical public health priority for protecting the most vulnerable and youngest individuals in the population.
- RSV causes lung inflammation, resulting in severe breathing difficulties in infants
- Approximately half of infants contract the infection during their first few months alive
- Symptoms range from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- More than 20,000 UK babies need serious hospital treatment for RSV each year
- Few babies succumb to RSV complications each year in the UK
Uptake rates and expert recommendations
Since the RSV vaccine programme commenced in 2024, health officials have stressed the significance of pregnant women receiving their jab at the best time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery delivers approximately 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies through the placenta.
The messaging from health authorities remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These regional differences reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the national data demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to reach expectant mothers
- Geographic variations in vaccination coverage levels in different parts of England require targeted improvement
- Local healthcare systems modifying schemes to align with community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness provides real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this protective measure, the 80% reduction in admissions means thousands of infants protected against serious illness. Parents no longer face the troubling prospect of seeing their babies gasping for air or struggle to eat, symptoms that mark critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal breathing health, offering expectant mothers a active means to shield their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection led to devastating brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s promotion of the jab emphasises the profound consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to pregnant women navigating their final trimester, transforming what was once an unavoidable seasonal threat into a manageable health risk.